医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Enzychem Lifesciences Announces Poster Presentation of EC-18 at the Radiation Research Society 2022 Annual Meeting

2022年07月25日 PM09:00
このエントリーをはてなブックマークに追加


 

ENGLEWOOD CLIFFS, N.J.

Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today the acceptance of a poster presentation at the Radiation Research Society (RRS) 2022 Annual Meeting, which will be held in Waikoloa, Hawaii on October 16-19, 2022.

The abstract highlights the radio-mitigative potential of its lead investigational compound, EC-18 in gastrointestinal acute radiation syndrome.

The details of the presentation are as follows:

Presentation Title: “Mitigation of gastrointestinal acute radiation syndrome by 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol via inhibition of necroptosis in mice”
Presenters: Drs. Yong Jae Kim and Jinseon Jeong
Date/Time: Wednesday, October 19, 17:15-18:30 HAST (11:15-12:30 ET)
Session: Radioprotection/Biodosimetry

“We are excited to present our results at the 2022 RRS conference, that support EC-18’s unique mechanism of action to potentially treat gastrointestinal acute radiation syndrome,” said Ki Young Sohn, CEO & Chairman of Enzychem Lifesciences. Based on these results, EC-18 has shown an effect on histopathological improvement of intestinal tissues, leading to functional restoration of the gastrointestinal tract.”

About Enzychem Lifesciences

Enzychem Lifesciences (KOSDAQ: 183490) is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with unmet medical needs in oncology, metabolic and inflammatory diseases. EC-18 acts as an immunomodulator, facilitating the resolution of inflammation and early return to homeostasis. Enzychem is headquartered in South Korea, with an office in the United States. For more information, please visit www.enzychem.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005090/en/

CONTACT

Investors / Media

Kimberly Ha

KKH Advisors

kimberly.ha@kkhadvisors.com

Sanghyun Lee

Enzychem Lifesciences

noah.lee@enzychem.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
  • 知临集团宣布发行 2023 年到期的 300 万美元可转换票据
  • ZCGの関連会社がユニバーサル・マリン・メディカル・サプライ・インターナショナルを買収
  • BiomeBank Continues Growth Trajectory With Over $10M Capital Raise
  • Medidata推出全新原生应用程序“myMedidata”,加速研究启动并提升患者体验